Altimmune (NASDAQ:ALT) Receives “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Altimmune (NASDAQ:ALT) in a report published on Monday,Benzinga reports. HC Wainwright currently has a $12.00 price target on the stock.

A number of other brokerages have also commented on ALT. Stifel Nicolaus assumed coverage on shares of Altimmune in a research note on Wednesday, January 8th. They issued a “buy” rating and a $18.00 price target for the company. William Blair started coverage on shares of Altimmune in a report on Friday. They issued a “market perform” rating on the stock. Finally, UBS Group initiated coverage on shares of Altimmune in a research note on Tuesday, November 12th. They set a “buy” rating and a $26.00 target price for the company. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Altimmune has an average rating of “Moderate Buy” and a consensus target price of $20.83.

Altimmune Trading Down 9.9 %

Shares of ALT opened at $5.99 on Monday. The company has a market cap of $426.04 million, a price-to-earnings ratio of -3.86 and a beta of 0.19. The business’s fifty day simple moving average is $6.81 and its two-hundred day simple moving average is $7.20. Altimmune has a 12 month low of $5.28 and a 12 month high of $12.35.

Altimmune (NASDAQ:ALT) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.01. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The company had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.00 million. As a group, research analysts forecast that Altimmune will post -1.35 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Larson Financial Group LLC purchased a new stake in shares of Altimmune in the 3rd quarter worth $31,000. SBI Securities Co. Ltd. bought a new stake in Altimmune during the fourth quarter valued at about $45,000. Virtus ETF Advisers LLC purchased a new stake in Altimmune in the fourth quarter worth about $60,000. Cullen Frost Bankers Inc. bought a new position in shares of Altimmune in the fourth quarter worth about $72,000. Finally, Sunbelt Securities Inc. lifted its position in shares of Altimmune by 356.8% during the 4th quarter. Sunbelt Securities Inc. now owns 10,844 shares of the company’s stock valued at $79,000 after buying an additional 8,470 shares in the last quarter. 78.05% of the stock is currently owned by institutional investors.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.